2160 logo

MicroPort CardioFlow Medtech Corporation Stock Price

SEHK:2160 Community·HK$2.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

2160 Share Price Performance

HK$0
-0.72 (-100.00%)
HK$0
-0.72 (-100.00%)
Price HK$0

2160 Community Narratives

There are no narratives available yet.

Snowflake Analysis

High growth potential with adequate balance sheet.

1 Risk
3 Rewards

MicroPort CardioFlow Medtech Corporation Key Details

CN¥367.5m

Revenue

CN¥113.6m

Cost of Revenue

CN¥253.9m

Gross Profit

CN¥249.1m

Other Expenses

CN¥4.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
0.002
69.09%
1.32%
11.5%
View Full Analysis

About 2160

Founded
2009
Employees
417
CEO
Ruinian Zhang
WebsiteView website
www.cardioflowmedtech.com

MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally. The company engages in research and development, manufacture, and sale of medical devices in the field of left atrial appendage, and treating valvular heart diseases, as well as properties management. It’s product portfolio includes transcatheter aortic valves, left atrial appendage closure, transcatheter mitral valves, transcatheter tricuspid valves, and surgical accessories, as well as procedural accessories; and VitaFlow, VitaFlow Liberty, VitaFlow Liberty Flex, Alwide Plus, AccuSniperTM, AnchorMan LAAC System, AnchorMan LAAA System, and various TAVI, TMV, TTV, and LAA products. In addition, the company provides technical consultation and technical services for medical devices clinical trial. MicroPort CardioFlow Medtech Corporation was founded in 2009 and is headquartered in Shanghai, China.